Loading...

Monensin Solution (1,000X)

Pricing & Availability
Regulatory Status
RUO
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Quantity Check Availability Save
420701 1 mL 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical Data Sheet (pdf)

Product Details

Formulation
Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
Concentration
2.0 mM
Storage & Handling
Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.
Application

ICFC - Quality tested
Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References
  1. Smeltz RB. 2007. J. Immunol. 178:4786.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Durkin ET,et al. 2008. Blood 10:1182.PubMed
  4. Durkin ET, et al. 2008. Blood 112:5245. PubMed
  5. Liu XS, et al. 2009. J. Immunol. 183:51. PubMed
  6. Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed
  7. Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed
  8. Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed
  9. Wood MW, et al. 2011. Infect Immun. 79:708. PubMed
  10. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  11. Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed
  12. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  13. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  14. Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations
  1. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  2. Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed
  3. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  4. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed
  5. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  6. Munk R, et al. 2011. PLoS One. 6:e18553. PubMed
  7. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  8. Aguilar-Pineda JA, et al. 2021. iScience. 24:102993. PubMed
  9. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  10. Durkin E, et al. 2008. Blood. 112:5245. PubMed
  11. Yang M, et al. 2010. J Immunol. 184:3321. PubMed
  12. Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
  13. Tian M, et al. 2022. J Clin Invest. 132:. PubMed
  14. Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
  15. Gao F, et al. 2021. Front Cell Infect Microbiol. 10:593805. PubMed
  16. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  17. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  18. Martens A, et al. 2020. Nat Immunol. 21:381. PubMed
  19. Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed
  20. Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed
  21. Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed
  22. Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed
  23. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  24. Datta A, et al. 2022. J Fungi (Basel). 8:. PubMed
  25. Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed
  26. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed
  27. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  28. Geisness AC, et al. 2021. Haematologica. Online ahead of print. PubMed
  29. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  30. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  31. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  32. Steinbuck MP, et al. 2021. Sci Adv. 7: . PubMed
  33. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  34. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  35. Shenoy AT, et al. 2021. Nat Commun. 12:5834. PubMed
  36. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  37. Elliott PR, et al. 2021. Cell Rep. 37:109777. PubMed
  38. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  39. Uddin MN, et al. 2022. Brain Behav Immun Health. 26:100563. PubMed
  40. Mittal P, et al. 2020. Cancers (Basel). :12. PubMed
  41. Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed
  42. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  43. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  45. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  46. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  47. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  48. Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed
  49. Krishnan A, et al. 2020. Am J Pathol. 190:1284. PubMed
  50. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  51. Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed
  52. Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed
  53. Liu X, et al. 2009. J Immunol. 183:51:00. PubMed
  54. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  55. de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed
  56. Shafer S, et al. 2021. J Allergy Clin Immunol. 148:256. PubMed
  57. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  58. Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed
  59. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  60. Wood M, et al. 2011. Infect Immun. 79:708. PubMed
  61. Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed
  62. Bunse C, et al. 2013. PLoS One. 8:77925. PubMed
  63. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  64. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  65. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  66. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  67. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  68. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  69. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  70. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  71. Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed
  72. Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed
  73. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  74. Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed
  75. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  76. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  77. Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed
  78. Kumar S, et al. 2021. JCI Insight. 6:e145228. PubMed
  79. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID
NA

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account